Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (61-70 of 1,137) with videos related to

Pageof 114
Sort By:
Clinical Cardiology|October 4, 2003
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part IIChristopher P Cannon
Pharmacoeconomics|May 7, 2005
Cost-effectiveness of clopidogrelChristopher P Cannon
American Heart Journal|February 28, 2002
To cath or not to cath? That used to be the questionChristopher P Cannon
Clinical Cornerstone|May 3, 2008
Cardiovascular disease and modifiable cardiometabolic risk factorsChristopher P Cannon
European Heart Journal|April 24, 2002
Enoxaparin in ST elevation MI - a bright futureC P Cannon
Journal of Thrombosis and Thrombolysis|June 12, 1999
Advances in the medical management of acute coronary syndromesC P Cannon
The American Journal of Geriatric Cardiology|June 21, 2001
Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional TherapiesChristopher P. Cannon
Clinical Cardiology|December 29, 2000
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trialsC P Cannon
Journal of Internal Medicine|March 8, 2008
Combination therapy in the management of mixed dyslipidaemiaC P Cannon
Critical Pathways in Cardiology|March 15, 2008
Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapyChristopher P Cannon
Pageof 114

Showing results (61-70 of 1,137) with videos related to

Sort By:
Pageof 114
Clinical Cardiology|October 4, 2003
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part IIChristopher P Cannon
Pharmacoeconomics|May 7, 2005
Cost-effectiveness of clopidogrelChristopher P Cannon
American Heart Journal|February 28, 2002
To cath or not to cath? That used to be the questionChristopher P Cannon
Clinical Cornerstone|May 3, 2008
Cardiovascular disease and modifiable cardiometabolic risk factorsChristopher P Cannon
European Heart Journal|April 24, 2002
Enoxaparin in ST elevation MI - a bright futureC P Cannon
Journal of Thrombosis and Thrombolysis|June 12, 1999
Advances in the medical management of acute coronary syndromesC P Cannon
The American Journal of Geriatric Cardiology|June 21, 2001
Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional TherapiesChristopher P. Cannon
Clinical Cardiology|December 29, 2000
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trialsC P Cannon
Journal of Internal Medicine|March 8, 2008
Combination therapy in the management of mixed dyslipidaemiaC P Cannon
Critical Pathways in Cardiology|March 15, 2008
Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapyChristopher P Cannon
Pageof 114